J Lawrence Marsh|Judit Pallos|Leslie M Thompson - JoVE Visualize

Showing results (1-10 of 258) with videos related to

Pageof 26

Sort By:

Human Molecular Genetics|August 20, 2003

Fly models of Huntington's diseaseJ Lawrence Marsh, Judit Pallos, Leslie M Thompson

Neuro-Degenerative Diseases|September 14, 2011

Pcaf modulates polyglutamine pathology in a Drosophila model of Huntington's diseaseLaszlo Bodai, Judit Pallos, Leslie Michels Thompson, et al.

Human Molecular Genetics|September 3, 2008

Inhibition of specific HDACs and sirtuins suppresses pathogenesis in a Drosophila model of Huntington's diseaseJudit Pallos, Laszlo Bodai, Tamas Lukacsovich, et al.

Human Molecular Genetics|May 25, 2006

Biologically active molecules that reduce polyglutamine aggregation and toxicityUrvee A Desai, Judit Pallos, Aye Aye K Ma, et al.

Neuron|November 19, 2003

A rapid cellular FRET assay of polyglutamine aggregation identifies a novel inhibitorSonia K Pollitt, Judit Pallos, Jieya Shao, et al.

Proceedings of the National Academy of Sciences of the United States of America|February 18, 2005

Identification of combinatorial drug regimens for treatment of Huntington's disease using DrosophilaNamita Agrawal, Judit Pallos, Natalia Slepko, et al.

Human Molecular Genetics|December 7, 2005

Mutant huntingtin alters MAPK signaling pathways in PC12 and striatal cells: ERK1/2 protects against mutant huntingtin-associated toxicityBarbara L Apostol, Katalin Illes, Judit Pallos, et al.

Neurobiology of Disease|May 13, 2021

Dopamine neuron-specific LRRK2 G2019S effects on gene expression revealed by translatome profilingJudit Pallos, Sophia Jeng, Shannon McWeeney, et al.

Proceedings of the National Academy of Sciences of the United States of America|August 3, 2005

Suppression of Huntington's disease pathology in Drosophila by human single-chain Fv antibodiesWilliam J Wolfgang, Todd W Miller, Jack M Webster, et al.

Neurobiology of Disease|May 17, 2012

Histone deacetylase (HDAC) inhibitors targeting HDAC3 and HDAC1 ameliorate polyglutamine-elicited phenotypes in model systems of Huntington's diseaseHaiqun Jia, Judit Pallos, Vincent Jacques, et al.

Pageof 26

Showing results (1-10 of 258) with videos related to

Sort By:

Pageof 26

Human Molecular Genetics|August 20, 2003

Fly models of Huntington's diseaseJ Lawrence Marsh, Judit Pallos, Leslie M Thompson

Neuro-Degenerative Diseases|September 14, 2011

Pcaf modulates polyglutamine pathology in a Drosophila model of Huntington's diseaseLaszlo Bodai, Judit Pallos, Leslie Michels Thompson, et al.

Human Molecular Genetics|September 3, 2008

Inhibition of specific HDACs and sirtuins suppresses pathogenesis in a Drosophila model of Huntington's diseaseJudit Pallos, Laszlo Bodai, Tamas Lukacsovich, et al.

Human Molecular Genetics|May 25, 2006

Biologically active molecules that reduce polyglutamine aggregation and toxicityUrvee A Desai, Judit Pallos, Aye Aye K Ma, et al.

Neuron|November 19, 2003

A rapid cellular FRET assay of polyglutamine aggregation identifies a novel inhibitorSonia K Pollitt, Judit Pallos, Jieya Shao, et al.

Proceedings of the National Academy of Sciences of the United States of America|February 18, 2005

Identification of combinatorial drug regimens for treatment of Huntington's disease using DrosophilaNamita Agrawal, Judit Pallos, Natalia Slepko, et al.

Human Molecular Genetics|December 7, 2005

Mutant huntingtin alters MAPK signaling pathways in PC12 and striatal cells: ERK1/2 protects against mutant huntingtin-associated toxicityBarbara L Apostol, Katalin Illes, Judit Pallos, et al.

Neurobiology of Disease|May 13, 2021

Dopamine neuron-specific LRRK2 G2019S effects on gene expression revealed by translatome profilingJudit Pallos, Sophia Jeng, Shannon McWeeney, et al.

Proceedings of the National Academy of Sciences of the United States of America|August 3, 2005

Suppression of Huntington's disease pathology in Drosophila by human single-chain Fv antibodiesWilliam J Wolfgang, Todd W Miller, Jack M Webster, et al.

Neurobiology of Disease|May 17, 2012

Histone deacetylase (HDAC) inhibitors targeting HDAC3 and HDAC1 ameliorate polyglutamine-elicited phenotypes in model systems of Huntington's diseaseHaiqun Jia, Judit Pallos, Vincent Jacques, et al.

Pageof 26